WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Guidelines recommend biochemical monitoring of patients treated with antihypertensive agents, although there is little primary evidence for these recommendations. WHAT THIS STUDY ADDS: Patients treated for hypertension in general practice often have no biochemical tests before, or in the 6 months after, starting drug treatment. AIMS: Guidelines on the management of hypertension have recommended baseline testing of serum electrolyte and creatinine concentrations before treatment since the 1990s. We wished to examine the extent of laboratory monitoring in patients with newly diagnosed hypertension and newly treated with antihypertensive drugs. METHODS: We carried out a retrospective analysis of 74,096 patients in the General Practice Research Database (GPRD) aged 18 years and older with newly diagnosed hypertension and prescribed a single antihypertensive agent. We determined the number of patients with a laboratory test for serum electrolyte and creatinine (or urea) concentrations prior to the first antihypertensive drug prescription and in the 6 months after and patient factors associated with subsequent monitoring. RESULTS: Thirty-four thousand nine hundred and forty-seven patients (47%) had at least one biochemical test in the 12 months prior to beginning antihypertensive treatment, and 26,946 (36%) had at least one biochemical monitoring test in the 6 months after beginning antihypertensive treatment. Thirteen thousand five hundred and four (18%) had both baseline and monitoring tests. Baseline tests were normal in 11,671 patients (86%), of whom 10,213 (88%) had normal tests at first monitoring. Monitoring was significantly more likely in patients treated with ACE inhibitors than thiazides (adjusted OR 1.90; 95% CI 1.80, 2.00), older patients (adjusted OR 1.23; 95% CI 1.11, 1.36) [individuals aged 80-89 years compared with <40 years], and patients with diabetes mellitus (adjusted OR 2.03; 95% CI 1.91, 2.16). CONCLUSION: Biochemical testing at baseline and monitoring after starting treatment is often omitted in newly diagnosed hypertensive patients. When both are tested, one in eight normal results becomes abnormal.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Guidelines recommend biochemical monitoring of patients treated with antihypertensive agents, although there is little primary evidence for these recommendations. WHAT THIS STUDY ADDS: Patients treated for hypertension in general practice often have no biochemical tests before, or in the 6 months after, starting drug treatment. AIMS: Guidelines on the management of hypertension have recommended baseline testing of serum electrolyte and creatinine concentrations before treatment since the 1990s. We wished to examine the extent of laboratory monitoring in patients with newly diagnosed hypertension and newly treated with antihypertensive drugs. METHODS: We carried out a retrospective analysis of 74,096 patients in the General Practice Research Database (GPRD) aged 18 years and older with newly diagnosed hypertension and prescribed a single antihypertensive agent. We determined the number of patients with a laboratory test for serum electrolyte and creatinine (or urea) concentrations prior to the first antihypertensive drug prescription and in the 6 months after and patient factors associated with subsequent monitoring. RESULTS: Thirty-four thousand nine hundred and forty-seven patients (47%) had at least one biochemical test in the 12 months prior to beginning antihypertensive treatment, and 26,946 (36%) had at least one biochemical monitoring test in the 6 months after beginning antihypertensive treatment. Thirteen thousand five hundred and four (18%) had both baseline and monitoring tests. Baseline tests were normal in 11,671 patients (86%), of whom 10,213 (88%) had normal tests at first monitoring. Monitoring was significantly more likely in patients treated with ACE inhibitors than thiazides (adjusted OR 1.90; 95% CI 1.80, 2.00), older patients (adjusted OR 1.23; 95% CI 1.11, 1.36) [individuals aged 80-89 years compared with <40 years], and patients with diabetes mellitus (adjusted OR 2.03; 95% CI 1.91, 2.16). CONCLUSION: Biochemical testing at baseline and monitoring after starting treatment is often omitted in newly diagnosed hypertensivepatients. When both are tested, one in eight normal results becomes abnormal.
Authors: Susan S Jick; James A Kaye; Catherine Vasilakis-Scaramozza; Luis A Garcia Rodríguez; Ana Ruigómez; Christoph R Meier; Raymond G Schlienger; Corri Black; Hershel Jick Journal: Pharmacotherapy Date: 2003-05 Impact factor: 4.705
Authors: L Ramsay; B Williams; G Johnston; G MacGregor; L Poston; J Potter; N Poulter; G Russell Journal: J Hum Hypertens Date: 1999-09 Impact factor: 3.012
Authors: Marsha A Raebel; David L McClure; Steven R Simon; K Arnold Chan; Adrianne C Feldstein; Margaret J Gunter; Jennifer Elston Lafata; Leslie Harrold; Winnie W Nelson; Richard Platt Journal: Ann Pharmacother Date: 2006-02-14 Impact factor: 3.154
Authors: Jan C van Blijderveen; Sabine M Straus; Maria A de Ridder; Bruno H Stricker; Miriam C Sturkenboom; Katia M Verhamme Journal: Drug Saf Date: 2014-05 Impact factor: 5.606
Authors: Janet E M Bootsma; Margreet F Warlé-van Herwaarden; André L M Verbeek; Peter Füssenich; Peter A G M De Smet; Marcel G Olde Rikkert; Cornelis Kramers Journal: Drug Saf Date: 2011-07-01 Impact factor: 5.606
Authors: Edouard L Fu; Marco Trevisan; Catherine M Clase; Marie Evans; Bengt Lindholm; Joris I Rotmans; Merel van Diepen; Friedo W Dekker; Juan-Jesus Carrero Journal: Clin J Am Soc Nephrol Date: 2019-08-08 Impact factor: 8.237
Authors: Danielle M Nash; Scott Brimble; Maureen Markle-Reid; Eric McArthur; Karen Tu; Gihad E Nesrallah; Allan Grill; Amit X Garg Journal: Can J Kidney Health Dis Date: 2017-05-23